MedPath

Investigation on the remission maintaining effect of Polaprezinc in patients with Crohn's disease in remission phase.

Not Applicable
Recruiting
Conditions
Patients with Crohn&#39
s disease in remission phase
Registration Number
JPRN-UMIN000005970
Lead Sponsor
Kawasaki Medical School
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

1)Patients who had undergone total parental nutrition. 2)Patients with serious liverdysfunction and renaldysfunction 3)Patients with serious heart disease ,lung disease and hemo? 4)Patients with malignancy 5)Patients who has a allergic history against Polaprezinc 6)Patients who are pregnant or have the possibility of pregnancy 7)The patient who was judged for unsuitable by responsibility doctor.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Crohn's disease activity index at 0,1,3,6,12 months after treatment and 1 month after end point.
Secondary Outcome Measures
NameTimeMethod
Recurrence rate Evaluation of subjective symptoms QOL(F-8) safty change of labolatory data
© Copyright 2025. All Rights Reserved by MedPath